Bioactivity | SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity[1][2][3]. |
Invitro | SB02024(5 μM,48 小时)在 B16-F10 和 CT26 肿瘤细胞中通过 STAT1/IRF7 诱导 CCL5 和 CXCL10[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SB02024 相关抗体: Western Blot Analysis[1] Cell Line: |
In Vivo | SB02024(20 mg/kg,口服灌胃)可减少肿瘤生长并提高抗 PD-L1/PD-1 的效果[1]。SB02024 会增加 B16-F10 和 CT26 荷瘤小鼠血浆中 CCL5 和 CXCL10 的水平,但不会增加非荷瘤小鼠血液中 CCL5 或 CXCL10 的水平[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
CAS | 2126737-28-6 |
Formula | C16H22F3N3O2 |
Molar Mass | 345.36 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Noman MZ, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. Sci Adv. 2020 Apr 29;6(18):eaax7881. [2]. Yu Y, et al. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. Mol Oncol. 2024 Mar 20. [3]. Bassam Claude JANJI, et al. Biomarker. Patent WO2020008046 A1. |